BGPT: Paper Review: Targeting histone acetylation/deacetylation in parasites: an update (2017

Explore by Goal

Quick Explanation Copied

Core take-away (skeptical + evidence-bound)

The review argues that epigenetic “acetylation/deacetylation” regulators (HATs, bromodomains, HDACs, and parasite sirtuins) provide promising anti-parasitic leverage across malaria, schistosomiasis, leishmaniasis, and Chagas disease, but it repeatedly emphasizes that parasite–host selectivity and in vivo translation remain unresolved. The authors’ synthesis is strongest where they cite direct enzyme inhibition + parasite growth/acetylation readouts, and weakest where it relies on potency without consistent in vivo therapeutic windows.

Long Explanation

Paper review (visual-first): Targeting histone acetylation/deacetylation in parasites: an update (2017–2020)

Bibliographic anchor: Fioravanti et al., Current Opinion in Chemical Biology (2020), DOI: 10.1016/j.cbpa.2020.05.008.

What the review covers (and what it doesn’t)

Coverage window: literature updates from 2017 to early 2020 (review perspective, not new experiments).
Therapeutic concept: epigenetic modulation (“epidrugs”) as a strategy for parasitic disease control, leveraging conserved chromatin regulators.
Not a systematic review: it’s an “opinion”/narrative update—so it may be subject to selection bias in which studies were highlighted.

Visual map: target classes → parasite readouts → key bottlenecks

Interpretation guide: The review’s repeated “through-line” is that epidrug enzyme-class hits can be biologically plausible, but translation is constrained by (i) selectivity and (ii) consistent in vivo efficacy.

Evidence strength checklist (how to “audit” a narrative review)

Audit step	What to look for in cited studies	Why it matters (skeptical rationale)	Where the review is strongest
Target engagement	Biochemical enzyme inhibition / binding (e.g., docking + enzyme assays)	Prevents “compound works for unknown reasons”	Often reported for PfGCN5/BRD/HDAC series as inhibition + acetylation marker changes
Phenotype coupling	Parasite proliferation/stage-specific killing consistent with acetylation logic	Avoids attributing causality to correlated markers	Several sections highlight stage impacts and/or dual-stage activity
Selectivity window	Compare parasite potency vs mammalian cells (IC50/toxicity, selectivity indices)	Therapeutic window is central; “potent in vitro” may still fail	The review identifies selectivity as an overarching unresolved issue
In vivo translation	PK/PD-supported efficacy in relevant models	Rules out false positives from cell culture conditions	The review explicitly notes reservations/inconsistency, e.g., a potent malaria HDACi failing in a rodent model

Section-by-section critique (what’s convincing vs uncertain)

1) Malaria (Plasmodium): HAT, BRD, HDAC—promising mechanistic threads, translation friction

Target inventory framing: the review describes genome-wide identification of HAT/HDAC candidates and highlights PfGCN5 and PfGCN5-related biology as a stress-responsive regulator connected to artemisinin resistance emergence.
Example coherence: the review includes cases where inhibition is followed by reduced parasite growth and concurrent acetylation marker logic (e.g., HAT/HDAC inhibitor action with biochemical or cellular acetylation readouts).
Counterpoint: natural products and multi-target chemotypes can produce “pleiotropic” effects; the review itself notes that multiple mechanisms cannot be excluded in some examples.
Translation friction: even when potency is strong, at least one potent malaria HDACi is described as failing to reduce parasitemia in an in vivo rodent model, plausibly due to pharmacokinetics.

2) Schistosomiasis (Schistosoma mansoni): HDAC8/SIRT2 are highlighted as more “reliably actionable,” but selectivity varies

Drug-class testing: the review discusses testing of multiple FDA-approved HDAC inhibitors across schistosomula/adult/egg readouts, reporting partial inhibition patterns rather than uniform effectiveness.
Target-directed chemistry: SmHDAC8 inhibitor series are described as arising from molecular modeling/virtual screening using SmHDAC8 structural information.
Selectivity variability: several inhibitor classes show differences between enzyme potency/selectivity and worm-level effects (e.g., favorable enzyme selectivity but limited worm activity).
SIRT2 example: SmSIRT2 is presented as a comparatively promising chemical target with analog series claiming improved potency/selectivity and reduction of viability, pairing, and egg laying (with no toxicity reported in cited cellular screens).

3) Leishmaniasis + Chagas disease (kinetoplastids): sirtuins appear “most reliable” in the review’s framing

Leishmania—HDACi failures/weakness: the review states that FDA-approved HDAC inhibitors tested at certain concentrations were ineffective and/or too toxic in macrophage contexts, and showed poor parasite inhibition for L. donovani forms.
Leishmania sirtuins (LiSIR2rp1 etc.): the review describes BNIP compounds as inhibiting parasite sirtuin LiSIR2rp1 with some selectivity vs hSIRT1.
Chagas (Trypanosoma cruzi): sirtuin-targeting chemotypes are used to explain (sub)micromolar effects in cellular assays but also include an example of in vivo failure likely due to pharmacokinetics.
Big skeptical point: the review repeatedly relies on correlational or mechanistic proxy evidence (acetylation changes, morphology, growth), and cautions that off-target effects and pleiotropy can’t always be ruled out.

Global conclusion of the review (what you should take away)

Promise: modulators of histone acetylation status “appear to be effective drugs” in protozoan infection contexts as summarized in 2017–2020 literature.
Most plausible target classes per parasite family: PfGCN5/HAT inhibitors and BRD inhibitors for malaria; SmHDAC8 and SmSIRT2 for schistosomiasis; parasite sirtuins for kinetoplastids are framed as “most reliable.”
Hard constraints: parasite-over-host selectivity and sufficient in vivo efficacy remain major bottlenecks.
Mechanistic extension: the authors suggest studying how epidrugs modulate host defense mechanisms by altering host acetylation/deacetylation states at gene promoters after infection.

Skeptical “what could disprove this” (as a reviewer)

Mechanism mismatch: for any claim that epidrugs primarily act via parasite histone acetylation/deacetylation, a decisive disproof would be consistent findings that (i) enzyme inhibition doesn’t occur at achievable exposures or (ii) chromatin/acetylation markers don’t shift in the parasite under conditions that still show phenotypic effects (i.e., phenotype becomes off-target-driven).
Translation failure not explained by PK: if improvements in PK/PD do not recover efficacy while maintaining enzyme engagement, then the core target hypothesis weakens.
Selectivity ceiling: if parasite-selective potency collapses when tested across broader host cell panels/primary cells, the therapeutic-window argument fails.

Note: these disproof criteria follow directly from the review’s own stated emphasis on selectivity, pleiotropy, and inconsistent in vivo efficacy, rather than from external assumptions.

Compact “data availability” audit

Critical point: This paper is a review; it does not generate new datasets by itself. That means reproducibility depends on the underlying primary studies’ methods/data reporting rather than on this review’s transparency for new raw data.

The TEI text provided here does not include dataset accession numbers for the review itself (consistent with it being a narrative synthesis).

Optional: deeper BGPT navigation (author-centric)

Feedback:

Updated: April 08, 2026